The management of chronicity requires a considerable commitment of resources and continuity of assistance.
Kidney cancer accounts for 4% of all cancers. For the most recently diagnosed cases, survival is five years for about 70% of patients.
To date, there are no tumor markers for diagnosis that is mainly based on imaging, such as ultrasound or computed tomography (CT).
- Monitor the QOL of patients on therapy.
- Intercepting low-grade adverse events to prevent them from becoming high-grade and to reduce unnecessary access to hospitals and emergency rooms.
- Allow doctors to receive constant reports on the patient's subjective condition.
- Produce anonymized aggregate data.
Kerubin's solution for managing the treatment of metastatic renal cell carcinoma.
Advanced solutions for the integration of services dedicated to the care of patients with kidney cancer.
Efficient, effective and integrated management with the Territory, through 24-hour assistance that helps to improve the quality of life of the cancer patient.
Use of a mixed analogue-digital communication in the doctor-patient relationship, through the Kerubin App which can also be consulted by patients at home for the correct and timely management of events related to the treatment and for verifying adherence to therapy.
Constant measurement of data on a dedicated Web App to assess therapeutic adherence and the related economic impact.
Implementation of a Real Life data monitoring system.